A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia

Trial Profile

A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Endothelial stem cell therapy (Primary)
  • Indications Angina pectoris; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RENEW
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 11 Dec 2015 Status changed from active, no longer recruiting to completed according to to ClinicalTrials.gov record.
    • 22 May 2015 Planned End Date changed from 1 Jun 2016 to 1 Nov 2015, according to to ClinicalTrials.gov record.
    • 22 May 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top